Literature DB >> 28281107

Cannabis for Pain and Headaches: Primer.

Philip S Kim1, Michael A Fishman2.   

Abstract

PURPOSE OF REVIEW: Marijuana has been used both medicinally and recreationally since ancient times and interest in its compounds for pain relief has increased in recent years. The identification of our own intrinsic, endocannabinoid system has laid the foundation for further research. RECENT
FINDINGS: Synthetic cannabinoids are being developed and synthesized from the marijuana plant such as dronabinol and nabilone. The US Food and Drug Administration approved the use of dronabinol and nabilone for chemotherapy-associated nausea and vomiting and HIV (Human Immunodeficiency Virus) wasting. Nabiximols is a cannabis extract that is approved for the treatment of spasticity and intractable pain in Canada and the UK. Further clinical trials are studying the effect of marijuana extracts for seizure disorders. Phytocannabinoids have been identified as key compounds involved in analgesia and anti-inflammatory effects. Other compounds found in cannabis such as flavonoids and terpenes are also being investigated as to their individual or synergistic effects. This article will review relevant literature regarding medical use of marijuana and cannabinoid pharmaceuticals with an emphasis on pain and headaches.

Entities:  

Keywords:  Cannabinoids; Cannabis; Headache; Marijuana; Nociception; Pain; Tetrahydrocannabinols

Mesh:

Substances:

Year:  2017        PMID: 28281107     DOI: 10.1007/s11916-017-0619-7

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  79 in total

Review 1.  Medicinal cannabis: rational guidelines for dosing.

Authors:  Gregory T Carter; Patrick Weydt; Muraco Kyashna-Tocha; Donald I Abrams
Journal:  IDrugs       Date:  2004-05

Review 2.  Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review.

Authors:  Jeanette M Tetrault; Kristina Crothers; Brent A Moore; Reena Mehra; John Concato; David A Fiellin
Journal:  Arch Intern Med       Date:  2007-02-12

Review 3.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

4.  Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons.

Authors:  Simon Akerman; Philip R Holland; Peter J Goadsby
Journal:  J Pharmacol Exp Ther       Date:  2006-10-03       Impact factor: 4.030

5.  Cannabinoid-opioid interaction in chronic pain.

Authors:  D I Abrams; P Couey; S B Shade; M E Kelly; N L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

6.  Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses.

Authors:  N M Strangman; J M Walker
Journal:  J Neurophysiol       Date:  1999-07       Impact factor: 2.714

7.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.

Authors:  Jonathan S Berman; Catherine Symonds; Rolfe Birch
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

8.  Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

Authors:  R B C Kavia; D De Ridder; C S Constantinescu; C G Stott; C J Fowler
Journal:  Mult Scler       Date:  2010-09-09       Impact factor: 6.312

Review 9.  Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Authors:  Ethan B Russo
Journal:  Neuro Endocrinol Lett       Date:  2004 Feb-Apr       Impact factor: 0.765

10.  Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain.

Authors:  Kevin F Boehnke; Evangelos Litinas; Daniel J Clauw
Journal:  J Pain       Date:  2016-03-19       Impact factor: 5.820

View more
  5 in total

Review 1.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

2.  Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?

Authors:  Jennifer H Martin; Jennifer Schneider; Catherine J Lucas; Peter Galettis
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

3.  Chronic migraine caused a higher rate of tendency to cannabinoid agonist compared to morphine.

Authors:  Mojdeh Mansoori; Mohammad Reza Zarei; Goli Chamani; Masoud Nazeri; Fatemeh Mohammadi; Samane Sadat Alavi; Mohammad Shabani
Journal:  Acta Biomed       Date:  2020-12-21

4.  Personal experience and attitudes of pain medicine specialists in Israel regarding the medical use of cannabis for chronic pain.

Authors:  Haggai Sharon; Noam Goldway; Itay Goor-Aryeh; Elon Eisenberg; Silviu Brill
Journal:  J Pain Res       Date:  2018-07-31       Impact factor: 3.133

5.  Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.

Authors:  Jerome Sarris; Justin Sinclair; Diana Karamacoska; Maggie Davidson; Joseph Firth
Journal:  BMC Psychiatry       Date:  2020-01-16       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.